New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
A Randomized, Discontinuation Phase 2 Study of Sorafenib vs. Placebo in Patients with Non-Small Cell Lung Cancer (NSCLC) Who Have Failed at Least Two Prior Chemotherapy Regimens
Preliminary findings from this randomized discontinuation Phase 2 study showed that treatment with Nexavar yielded encouraging results in heavily pre-treated patients with NSCLC. The study showed that patients who remained on Nexavar experienced a longer period of disease control and disease stabilization than patients who discontinued Nexavar after the initial run-in phase of treatment. In the study, the most common treatment-emergent adverse events included fatigue, hand/foot syndrome and skin rash.
This entry was posted on Monday, June 2nd, 2008 at 12:09 pm and is filed under Research, Non-Small-Cell. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.